Free Trial
NASDAQ:KALV

KalVista Pharmaceuticals (KALV) Stock Price, News & Analysis

KalVista Pharmaceuticals logo
$13.72 +0.13 (+0.96%)
As of 11:17 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About KalVista Pharmaceuticals Stock (NASDAQ:KALV)

Key Stats

Today's Range
$13.62
$13.96
50-Day Range
$11.31
$16.01
52-Week Range
$7.30
$16.32
Volume
88,612 shs
Average Volume
775,802 shs
Market Capitalization
$690.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.29
Consensus Rating
Buy

Company Overview

KalVista Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
74th Percentile Overall Score

KALV MarketRank™: 

KalVista Pharmaceuticals scored higher than 74% of companies evaluated by MarketBeat, and ranked 248th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    KalVista Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    KalVista Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about KalVista Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for KalVista Pharmaceuticals are expected to grow in the coming year, from ($3.56) to ($2.90) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of KalVista Pharmaceuticals is -3.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of KalVista Pharmaceuticals is -3.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    KalVista Pharmaceuticals has a P/B Ratio of 7.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about KalVista Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    22.50% of the float of KalVista Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    KalVista Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.
  • Change versus previous month

    Short interest in KalVista Pharmaceuticals has recently increased by 8.76%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    KalVista Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    KalVista Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    22.50% of the float of KalVista Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    KalVista Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.
  • Change versus previous month

    Short interest in KalVista Pharmaceuticals has recently increased by 8.76%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    KalVista Pharmaceuticals has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for KalVista Pharmaceuticals this week, compared to 5 articles on an average week.
  • MarketBeat Follows

    Only 3 people have added KalVista Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, KalVista Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $880,764.00 in company stock.

  • Percentage Held by Insiders

    Only 4.30% of the stock of KalVista Pharmaceuticals is held by insiders.

  • Read more about KalVista Pharmaceuticals' insider trading history.
Receive KALV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

KALV Stock News Headlines

A New Way to Double Your Retirement Income?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.tc pixel
See More Headlines

KALV Stock Analysis - Frequently Asked Questions

KalVista Pharmaceuticals' stock was trading at $8.47 at the beginning of the year. Since then, KALV stock has increased by 61.2% and is now trading at $13.65.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) posted its quarterly earnings data on Thursday, July, 10th. The specialty pharmaceutical company reported ($3.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by $2.86.

KalVista Pharmaceuticals' top institutional investors include Vestal Point Capital LP (9.36%), Octagon Capital Advisors LP (2.55%), Emerald Advisers LLC (2.08%) and Ameriprise Financial Inc. (1.89%). Insiders that own company stock include Venrock Healthcare Capital Par, Benjamin L Palleiko, Thomas Andrew Crockett, Paul K Audhya, Christopher Yea, Edward P Feener, Nicole Sweeny and Albert Cha.
View institutional ownership trends
.

Shares of KALV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that KalVista Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Chevron (CVX) and Netflix (NFLX).

Company Calendar

Last Earnings
7/10/2025
Today
8/28/2025
Next Earnings (Estimated)
9/04/2025
Fiscal Year End
4/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KALV
CIK
1348911
Employees
100
Year Founded
N/A

Price Target and Rating

High Price Target
$30.00
Low Price Target
$20.00
Potential Upside/Downside
+93.4%
Consensus Rating
Buy
Rating Score (0-4)
3.11
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.69)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$183.44 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-134.07%
Return on Assets
-82.65%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.35
Quick Ratio
5.35

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.92 per share
Price / Book
7.08

Miscellaneous

Outstanding Shares
50,340,000
Free Float
48,175,000
Market Cap
$684.12 million
Optionable
Optionable
Beta
0.05

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:KALV) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners